Three-dimensional neuronal cell culture: in pursuit of novel treatments for neurodegenerative disease by Carter, Sarah-Sophia et al.
University of Wollongong 
Research Online 
Australian Institute for Innovative Materials - 
Papers Australian Institute for Innovative Materials 
1-1-2017 
Three-dimensional neuronal cell culture: in pursuit of novel treatments for 
neurodegenerative disease 
Sarah-Sophia Carter 
University of Wollongong, ssdc758@uowmail.edu.au 
Xiao Liu 
University of Wollongong, xiaol@uow.edu.au 
Zhilian Yue 
University of Wollongong, zyue@uow.edu.au 
Gordon G. Wallace 
University of Wollongong, gwallace@uow.edu.au 
Follow this and additional works at: https://ro.uow.edu.au/aiimpapers 
 Part of the Engineering Commons, and the Physical Sciences and Mathematics Commons 
Recommended Citation 
Carter, Sarah-Sophia; Liu, Xiao; Yue, Zhilian; and Wallace, Gordon G., "Three-dimensional neuronal cell 
culture: in pursuit of novel treatments for neurodegenerative disease" (2017). Australian Institute for 
Innovative Materials - Papers. 2775. 
https://ro.uow.edu.au/aiimpapers/2775 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Three-dimensional neuronal cell culture: in pursuit of novel treatments for 
neurodegenerative disease 
Abstract 
To gain a better understanding of the underlying mechanisms of neurological disease, relevant tissue 
models are imperative. Over the years, this realization has fuelled the development of novel tools and 
platforms, which aim at capturing in vivo complexity. One example is the field of biofabrication, which 
focuses on fabrication of three-dimensional (3D) biologically functional products in a controlled and 
automated manner. Herein, we provide a general overview of classical 3D cell culture platforms, 
particularly in the context of neurodegenerative disease. Subsequently, the focus is put on bioprinting-
based biofabrication, its potential to advance 3D neuronal cell culture and, to conclude, the relevant 
translational bottlenecks, which will need to be considered as the field evolves. 
Disciplines 
Engineering | Physical Sciences and Mathematics 
Publication Details 
Carter, S. D., Liu, X., Yue, Z. & Wallace, G. (2017). Three-dimensional neuronal cell culture: in pursuit of 
novel treatments for neurodegenerative disease. MRS Communications, 7 (3), 320-331. 
This journal article is available at Research Online: https://ro.uow.edu.au/aiimpapers/2775 
 1 
Three-dimensional neuronal cell culture: in pursuit of novel 
treatments for neurodegenerative disease 
 
Sarah-Sophia D. Carter1,2, Xiao Liu1, Zhilian Yue1, and Gordon G. Wallace1* 
1ARC Centre of Excellence for Electromaterials Science, Intelligent Polymer Research 
Institute, AIIM Facility, University of Wollongong, NSW 2522, Australia 
2Utrecht University, Utrecht, the Netherlands 
 
* Address all correspondence to Gordon G. Wallace at gwallace@uow.edu.au 
 
 
Abstract 
To gain a better understanding of the underlying mechanisms of neurological disease, relevant 
tissue models are imperative. Over the years, this realization has fuelled the development of 
novel tools and platforms, which aim at capturing in vivo complexity. One example is the 
field of biofabrication, which focuses on fabrication of three-dimensional (3D) biologically 
functional products in a controlled and automated manner. Herein, we provide a general 
overview of classical 3D cell culture platforms, particularly in the context of 
neurodegenerative disease. Subsequently, the focus is put on bioprinting-based 
biofabrication; its potential to advance 3D neuronal cell culture and, to conclude, the 
relevant translational bottlenecks, which will need to be considered as the field evolves. 
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Introduction 
The vast majority of our current understanding of biological phenomena comes from routine 
classical cell culture experiments; growing of cells onto flat and rigid two-dimensional (2D) 
substrates. Even though these efforts have provided the research community with valuable 
insights into the mechanisms underlying a variety of biological processes, it is nowadays 
widely accepted that knowledge obtained from these studies might be too reductionist to 
accurately translate to the human situation.[1,2] Growing cells onto 2D substrates deviates 
significantly from the dynamic three-dimensional (3D) in vivo situation; cells lack tissue-
specific polarity, have limited contact with neighbouring cells, and are exposed to non-
physiologically uniform diffusion kinetics, which together alter how cells perceive and 
respond to their surrounding microenvironment (Fig. 1). [3-5] This discrepancy between 
traditional in vitro culture conditions and the in vivo environment has been recognized among 
a variety of research areas, including the area of neuroscience and more specifically 
neurological disease, the latter presenting a great challenge in modern medicine. [6] 
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Figure 1. Schematic representation of cells (a) cultured on a stiff 2D tissue culture substrate 
and (b) embedded in a more physiologically relevant 3D hydrogel environment, which has 
unique design variables (e.g. degradation sites and crosslinking mechanisms) that direct cell 
behaviour. In vivo, cells reside in a complex and dynamic environment, which provides 
binding ligands for cell adhesion and directs processes such as cell adhesion, proliferation, 
migration, and morphology. Cells grown onto classical tissue culture substrates are confined 
to a planar surface, which leads to abnormal integrin binding and (mechano) signalling 
cascades, resulting in aberrant phenotypes. In the transition towards the third dimension, 
hydrogel-based strategies play a pivotal role. Hydrogel matrices can be tuned to meet 
application-specific requirements (e.g. degradation rate, porosity, and mechanical properties. 
Adapted by permission from Macmillan Publishers Ltd: [NATURE METHODS] (7), 
copyright (2016). 
 
 
A glance at our nervous system 
Our nervous system encompasses two main cell types, neurons and glial cells, which both 
have a crucial role in nervous system functioning.[8,9] Neurons are highly polarized cells, 
responsible for the transfer and processing of electrical and chemical signals that regulate 
body function. According to their function, neurons can be classified into sensory neurons, 
motor neurons, and interneurons, which can be excitatory, inhibitory or modulatory in their 
effect. Typically, neurons consist of a cell body with projections, known as axons and 
dendrites. These projections can vary in terms of number and position, which is highly linked 
to neuronal function.[10] The non-neuronal glial cells come in a variety of subtypes and have 
different roles in the development, maintenance, and functioning of the nervous system.[11] 
For a long time, glial cells were regarded to have a relatively simple supportive function. 
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However, research over the past years has uncovered their vital role and active participation 
in the development and functioning of the nervous system. Beyond these cellular components 
and their intricate communication, appropriate nervous system functioning requires a highly 
regulated extracellular environment.[12] This dynamic mechanical and biochemical interplay 
plays a key role in many essential processes, including spatio-temporal cell signalling, cell 
identity, and cell function.[13-17] To gain more insights into neurological disorders and advance 
current health care, it is essential to recapitulate this complex relationship between neurons 
and their interaction with the surrounding environment, which requires more accurate in vitro 
nervous systems models.  
 
The rise of the third dimension 
Over the years, various strategies aiming at capturing 3D tissue physiology have been 
developed. Examples range from relatively simple approaches, such as the formation of 
cellular spheroids, to more sophisticated scaffold-based approaches.[18-21] Whereas scaffold-
free approaches mostly rely on the inherent tendency of adherent cells to form aggregates, 
scaffold-based approaches require a thorough consideration of a plethora of factors. Clearly, 
the scaffold-based environment should mimic the native niche as closely as possible, which 
calls for multidisciplinary expertise from biologist, engineers, and material scientists. 
Unfortunately, accurately recapitulating the complex nature of tissues and/or organs by means 
of traditional scaffold-based approaches remains challenging, especially when it comes to 
achieving precise architectural configurations and spatial positioning of (multiple) cells and 
scaffolding materials. To this end, the growing field of biofabrication offers an exciting 
toolbox.[22,23] As described by Groll et al., the term biofabrication refers to the automated 
generation of products with biological function by means of bioprinting or bioassembly and 
subsequent maturation processes.[24] More specifically, biofabrication approaches encompass 
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living cells, cell aggregates, bioactive molecules, and biomaterials to generate biologically 
functional products in an automated and highly organized manner.  
In this review, we focus on bioprinting-based biofabrication approaches and the potential to 
advance currently available 3D cell culture platforms for nervous system applications, 
particularly in the context of neurodegenerative diseases using Alzheimer’s disease as an 
example. Noteworthy, here we refer to bioprinting as the use of printing technology to pattern 
and/or organize biological entities in 2D or 3D as described by Derby.[25] After a brief 
description of the general concept of 3D cell culture platforms, an introduction into the field 
of bioprinting is provided. Subsequently, the potential of bioprinting technology and its 
emerging applications for the nervous system will be discussed. To conclude, we highlight 
possible translational bottlenecks, which will need to be addressed as the technology matures. 
Key aspects include the necessary advances in converging disciplines, the need for 
standardization in the field, and ethical regulations. 
 
 
Neural tissue engineering: the need for relevant 3D cell culture platforms 
Neurodegenerative disease is a collective term for a group of disorders which primarily affect 
neurons.[26] Whereas a variety of disorders (e.g. Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease) are covered by this umbrella term, in this review the focus is put on 
Alzheimer’s disease, which represents the most common cause of dementia among adults and 
affects millions of people worldwide. As reported by the World Health Organization (WHO), 
the number of people living with dementia is currently estimated at over 47 million, which is 
expected to almost triple by 2050.  
Alzheimer’s disease is clinically characterized by gradual deterioration in cognitive function, 
including progressive memory loss, impaired judgment, and changes in personality and 
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behaviour, which can become incapacitating at later stage of illness.[27-28] Besides the impact 
on patients’ quality of life, dementia is a tremendous social and economic challenge; the 
disease takes heavy toll on caregivers and has been identified as a major economic burden. [29-
31] 
At the cellular level, Alzheimer’s disease is characterized by damage to cortical neurons, 
particularly in the associative neocortex and hippocampus.[28,32] This neuronal damage is 
correlated to deposition and accumulation of abnormal proteins; extracellular amyloid-β 
peptides and intracellular filamentous hyperphosphorylated tau proteins, which are the core 
hallmarks of Alzheimer’s disease and also known as plaques and tangles respectively.[33] 
Whereas research was initially focused on neuronal cells and protein-mediated neuronal 
damage, it has become increasingly apparent that Alzheimer’s pathogenesis has a more 
complex nature and is not restricted to these events. Over the years research has evidenced 
that other factors, such as immunological mechanisms, have an accompanying role in the 
pathway leading to progression of the disease.[34] Despite progress in understanding the 
underlying mechanisms and aspects of neurodegenerative disease, there are still many 
unknowns. This is reflected by the lack of effective therapeutic options for the vast majority 
of these disorders, including Alzheimer’s disease, which are nowadays limited to 
symptomatic relief.[30,35] In order to advance the treatment of these disorders it is critical to 
gain a deeper understanding of processes such as neural network formation, organization, and 
functioning.  
 
Classical 3D cell culture strategies 
In response to the growing demand for more physiologically relevant models, a number of 3D 
cell culture platforms have been developed.[36,37] Examples range from cell-self-assembly-
based approaches, to scaffold-based approaches, and on-chip biomimicry. In the next section 
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we aim to sketch and illustrate the importance of these classical 3D cell culture platforms and 
capturing the third dimension.  
 
Cell-self-assembly-based approaches  
One of the most common cell-self-assembly-based approaches is the formation of cellular 
spheroids (Fig. 2). Spheroid formation is generally considered to be a relatively simple 3D 
cell culture method and has shown to be a convenient means towards more accurate tissue 
models. The main benefit of using spheroids over 2D monolayer cultures is the presence of 
more physiologically relevant diffusion gradients (e.g. oxygen and nutrients) and cell-cell and 
cell-ECM interactions.[36,38,39] With time, a variety of methods have been developed to 
produce spheroids, one well-known example being the hanging drop method.[36,38] In this 
approach, aliquots of cell suspensions are seeded on an adherent surface, which is 
subsequently reverted, yet allowing the droplets to stay attached due to surface tension, 
resulting in gravity-enforced cell aggregation at the bottom of the droplets. Alternative 
popular approaches are based on dynamic culture conditions (e.g. the spinner flask method), 
low-adhesive surfaces (e.g. forced-floating technique), and more recently, micro-/nano-
patterned surfaces and micromolding, the latter providing defined regions for cell 
immobilization and subsequent spheroid formation.[38] All these different methods are 
associated with their own advantages and disadvantages, resulting in spheroids of different 
sizes and shapes, and should be chosen depending on the experimental needs and final 
application.[36,39] 
 
To date, spheroids have been successfully generated from a variety of cell types, including 
neuronal cells.[40] For example, Dingle et al. generated neural spheroids from primary rat 
cortical tissues by means of micromolding, which were reproducible in size and cellular 
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composition.[41] Spheroid characterization revealed resemblance to in vivo cortical tissue in 
terms of stiffness, neuronal electrophysiology, neural cell types, and morphology. Following 
on from this study, Boutin et al. assessed the potential of this heterogeneous spheroid model 
to form capillary-like networks, the later playing an important role in protecting the neuronal 
environment.[42] Immunohistochemical analysis revealed that within three days, cortical 
endothelial cells seemed to form networks in the spheroids, which were surrounded by 
basement membrane components and relevant cell types. In future studies, this relatively 
simple model could offer valuable insights in understanding disorders linked to neurovascular 
dysfunction.  
 
A more advanced cell-self-assembly-based 3D cell culture platform that has been gaining 
increasing interest is the organoid model (Fig. 2).[43] Whereas various definitions are reported 
in the literature, here we refer to organoids as self-organizing 3D cell clusters, which can be 
established from different cell sources (e.g. primary cells, cell lines, stem cells), resembling 
the tissue architecture of origin.[37,44,45] Over the last decade, organoid technology has made 
tremendous progress and several in vitro organoids have been established.[37] Whereas the 
relatively scarce amount of literature on neuronal organoids is mainly focussing on 
neurodevelopmental phenomena, Raja et al. have shown its potential to study 
neurodegeneration.[45] In this study, neural organoids were formed from induced pluripotent 
stem cells derived from Alzheimer’s disease patients. This organoid model has shown to be 
robust, able to recapitulate both hallmarks of Alzheimer’s disease, and has been shown to be 
amenable to experimental manipulation in terms of drug treatment.  
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Figure 2. Cell culture platforms: monolayer culture on conventional tissue culture substrates, 
single cell in 3D matrix, spheroid culture, and organoid culture. Obtained and modified 
from[42] with permission from Elsevier. 
 
 
Biomaterial-aided 3D cell culture platforms 
In this section, we only focus on the non-biofabrication biomaterial-aided platforms that 
involve either pre-fabricated scaffolds for cell cultivation or polymer hydrogels for cell 
encapsulation. In both cases, the biomaterials do not only provide structural and mechanical 
support, but also guide the cells via acting as a template for tissue formation.[20,47,48] 
Intuitively, these biomaterials should resemble the dynamic native microenvironment of the 
specific target tissue as closely as possible, a task that can be extremely challenging; it does 
not only require the biological and functional integration of the cells with the surrounding 
biomaterial(s), but also careful consideration of biodegradability, mechanical properties, 
scaffold architecture, and manufacturing technology.[47,49] 
 
Over the years, a myriad of materials have been investigated for their potential to support 
neuronal 3D cell culture.[50] These range from natural polymers (e.g. collagen, hyaluronic 
acid, alginate, Matrigel, and silk) and synthetic polymers (e.g. poly(lactide-co-glycolide 
(PLGA), poly-L-lactic acid (PLLA), and polyurethane (PU)) to hybrid materials, metals, 
ceramics, glass, and carbon nanotubes. For example, Frampton et al. described a 3D culture 
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system based on cell entrapment in peptide-functionalized alginate hydrogels.[51] Cell viability 
and functional analysis of primary rat glial and neuronal cells demonstrated appropriate cell 
viability and metabolic function within the constructs over a period of 14 days. Interestingly, 
cell morphology, particularly of astrocytes differed from cells cultured on 2D substrates. 
Analysis of the functional activity of primary rat neurons showed formation of functional 
synaptic elements and electrical activity. Together, the results showed that this system could 
offer a viable cell culture platform to (co-)culture a variety of relevant cell types for use in 
neural cell culture, supporting cell type-specific function. Lai et al. compared neuronal 
voltage gated calcium channel functionality in 2D to 3D setting.[52] Primary neuronal cells 
were harvested from mice and either cultured onto 2D flat surfaces or in 3D synthetic 
polymer scaffolds, the latter consisting of PLLA and polystyrene. It was found that cells in 
3D scaffolds resembled native intact tissue more closely in terms of cell morphology and ion 
channel functioning. Another striking example that illustrates the importance of recapitulating 
an in vivo-like 3D cellular environment is described by Choi et al. who studied the pathogenic 
mechanisms of Alzheimer’s disease in a 3D Matrigel-based brain tissue-like environment.[53] 
Whereas amyloid-β is thought to diffuse into the culture medium in 2D systems and to be 
removed during regular media changes, it was found that this closed 3D culture model system 
promoted amyloid-β aggregation, thereby more closely recapitulating Alzheimer’s disease 
pathology. More recently, Kraus et al. developed a spheroidal co-culture model to examine 
neurite formation.[54] In this study, spheroids were formed from glial cells (i.e. Schwann cells) 
and neurons and subsequently encapsulated in a 3D collagen matrix. Evaluation of neurite 
lengths demonstrated a significant increase in neurite length after a period of seven days in 
the 3D set-up compared to 2D culture.  
 
Organ-on-a-chip technology 
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Organ-on-a-chip technology refers to microfluidic cell culture devices, which are designed to 
reconstitute critical tissue- and organ-level functions and rely on a sophisticated interplay 
between engineering and biology.[55,56] These systems are used for and offer control over a 
variety of key system parameters, including the choice of cells and their spatial positioning. 
However, the added value of on-chip biomimicry lies within its potential to control 
parameters that are not easily controlled in 3D static cultures or bioreactors (e.g. fluid flow, 
physical and chemical gradients), which makes them promising tools to address fundamental 
questions in the area of tissue development, organ physiology, and disease etiology.[56] 
 
Over the years, various microfluidic devices have been developed to provide insights into the 
pathophysiology of neurodegenerative disorders.[57] For example, Choi et al. and Cho et al. 
utilized a microfluidic-based approach to investigate the effects of amyloid-β (aggregation) on 
neurons and microglia respectively.[58,59] In their study, Choi et al. used a low-flow 
microfluidic system to assess the neurotoxicity of time-dependent amyloid-β aggregation and 
the effect of physiological flow on neuronal cell survival.[58] With their microfluidic platform, 
Cho et al. studied the effect of amyloid-β on microglial accumulation, which demonstrated a 
different role for soluble and bound amyloid-β during microglia recruitment and 
localization.[59] Another well-reported topic involves amyloid-β and tau protein propagation. 
Kunze et al. have utilized a microfluidic device to study the neurodegenerative propagation 
processes of Alzheimer’s disease.[60] Primary rat cortical neurons were cultured in two 
separated cell compartments, one housing diseased neurons (i.e. showing tau-
hyperphosporylation) and the other healthy neurons. By designing the microfluidic device in 
such a manner that connectivity was favoured through neurite outgrowth from both 
compartments over time, a co-pathological state within the same neural cell culture was 
established. More recent studies regarding amyloid-β and tau protein propagation are 
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presented by Song et al. who demonstrated amyloid-β spreading via neuronal connections 
along axonal membranes[61], Deleglise et al. who investigated the distant effects of local 
amyloid-β stress on neuronal subcompartments and networks[33], and Dujardin et al. and 
Calafate et al. who offered novel insights into tau protein transfer.[62,63] 
 
 
Bioprinting  
3D cell culture platforms provide the target tissues with a (temporary) microenvironment and 
thereby contribute to spatio-temporal cell signalling, cell identity, and cell function. Although 
these 3D cell culture platforms have been demonstrated to offer a promising route towards 
more physiologically relevant neuronal models and in-depth understanding of cellular 
behaviour and pathological conditions, there are still a number of limitations. One of the 
primary general challenges is related to the lack of adequate control. Regardless of the 
platform, issues such as irregular geometry (e.g. external shape and internal architecture of the 
scaffolds) and size, poor reproducibility, and difficulties regarding scaling-up impede their 
widespread use. To this end, bioprinting offers an exciting opportunity. By combining 
biomaterials, cells, and/or growth factors (composites referred to as bioink) with automated 
fabrication processes such as additive manufacturing (the generation of 3D constructs in a 
layer-by-layer manner based on a computer-aided design (CAD)), it facilitates the generation 
of 3D bio-engineered constructs with superior organization and more closely resembling 
native tissues.[22,23,24] This computer-controlled deposition of biologically relevant materials 
allows the fabrication of (multi)-cellular constructs. Besides, the layer-by-layer architecture 
allows tailoring beyond the cellular level, namely in terms of materials, and biochemical cues, 
which could be optimized to meet cell-specific requirements. In this manner, multiple cell 
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types could be contained throughout a single 3D construct, yet in an environment optimized 
for each of the individual components.  
 
Bioprinting technologies 
Although a wide variety of bioprinting technologies have been described in the literature, 
three main categories can be distinguished; inkjet printing, laser-assisted printing, and 
extrusion-based printing (Fig. 3).[64,65] 
 
 
Figure 3. Main bioprinting technologies: (a) Inkjet printing, (b) Laser-assisted printing (c) 
Extrusion printing. Figure obtained and modified from [23] with permission from John Wiley 
and Sons. 
 
 
Inkjet printing can be described as a noncontact printing process in which controlled volumes 
of (bio)ink (1–100 picolitres; 10–50 μm diameter) are dispensed on predefined locations, 
driven by thermal or piezoelectric forces (Fig. 3(a)). Both in thermal inkjet printing and 
piezoelectric inkjet printing, (bio)ink droplets are forced from the nozzle by creating a 
pressure pulse. In thermal inkjet printing, this pressure pulse is generated by heating. This 
heating results in vaporization of small volumes of the (bio)ink, producing the pulse required 
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to expel material from the nozzle. Piezoelectric inkjet printing involves the application of a 
direct mechanical pulse to the (bio)ink, which on its turn generates the pressure needed to 
force material though the nozzle. Regardless of the high resolution, relatively low cost, and 
wide availability of inkjet printing, several factors impede its successful widespread 
application.[23,65] These include the challenges regarding cell viability due to the small 
orifices, the potential risks of exposing the (bio)ink to thermal and mechanical stress, 
inconsistency in droplet size, nozzle clogging when using biologically relevant cell densities 
(>106 cells/ml), and the low upper viscosity limit of the (bio)ink (ideally < 10 mPa/s), which 
although considered to be beneficial for cell migration, proliferation, and cell viability, 
influences printing fidelity.[23,65] 
 
As the name indicates, laser-assisted printing encompasses a plethora of manufacturing 
technologies which utilize a laser to deposit (biological) materials on a substrate. Laser-
assisted bioprinting stems from the principles of a subclass of laser-assisted printing, namely 
laser-induced forward transfer (LIFT) (Fig. 3(b)). In LIFT approaches, a focused laser-source 
is used to transfer material from a so-called donor slide towards the receiving substrate. 
Typically the donor slide is covered with a laser energy absorbing layer and the desired 
(bio)ink. The focused laser pulse causes evaporation of the absorbing layer, leading to the 
formation a high-pressure bubble, which induces propulsion of the material. As this approach 
is nozzle free, the clogging issue associated with inkjet-based printing or extrusion-based 
printing is avoided. In addition, laser-assisted printing is compatible with materials with a 
broad range of viscosities (1–300 mPa/s) and able to deposit cells at medium cell density (i.e. 
108 cells/ml) without detrimental effects on cell viability.[23,64,65] Despite these advantages, the 
presence of metallic residues in the final construct, the challenging and time-consuming 
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nature of preparing individual ribbons, and relatively high costs are several examples of 
hurdles yet to clear. 
 
Nowadays, most of the commercially available bioprinters are based on extrusion-based 
dispensing (Fig. 3(c)). These systems function by robotically controlled extrusion of the 
(bio)ink, which is usually driven by mechanical action (piston or screw) or a pneumatic 
system, each posing their own (dis)advantages. Whereas mechanically driven deposition 
usually provides more control over the material flow, pneumatic systems have simpler drive-
mechanism components, the latter allowing for higher maximum force capabilities. In 
contrast to inkjet printers, which yield single droplets of material, extrusion printers yield 
continuous filaments of the (bio)ink, usually with a resolution in the order of 200 µm. 
Besides, extrusion printing is compatible with materials with a wide range of viscosities (30 – 
6×107 mPa/s). Even though the resolution is substantially lower when compared to laser- or 
inkjet-based systems, the fabrication speed, clinically relevant sizes, and ability to deposit 
high cell densities (>108 cells/ml) with high cell viability make this technology very 
promising for tissue engineering and regenerative medicine (TERM) applications.[23,65] 
  
Bioprinting in 3D neuronal cell culture 
Given that the field of bioprinting in general, and even more for this specific application, is 
still in its infancy, early studies of bioprinting in 3D neuronal culture have been focused 
mostly on healthy tissue. However, even though these studies do not directly concern diseased 
tissue(-like) constructs, these could be used as tool for a variety of applications, ranging from 
cell behaviour studies to understanding pathological conditions and drug testing, which is 
related to and relevant for neurodegenerative disease.  
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Various studies relating to this topic have been reported. Among these, several have been 
focussing on the effect of printing processes on cell viability. For example, Xu et al. and Xu 
et al. studied the delivery of neuronal cells by a modified thermal inkjet printer, and 
demonstrated no significant effect on cell survival.[66,67] More recently, Lorber et al. studied 
the potential of inkjet printing of adult rat retinal ganglion cells and retinal glia, demonstrating 
no significant difference in cell survival compared to non-printed controls.[68] In a similar 
approach, Tse et al. printed primary porcine Schwann cells and neuronal analogue NG108-15 
cells with a piezoelectric inkjet printer.[69] This study showed that a higher range of 
experimental voltages has no adverse effects over a period of seven days. Whereas these 
studies could be considered relatively simplistic in nature (i.e. printing of cells to explore 
compatibility with the printing modality) these efforts have illustrated that relevant cells can 
be delivered and positioned by means of inkjet printing approaches without substantial 
damage.  
A major advantage of bioprinting approaches is the ability to deliver and distribute cells and 
other biological factors in a very precisely controlled manner. An example is given by Lee et 
al. who fabricated cell–hydrogel composites for the purpose of in vitro neural culture.[70] 
Murine neural stem cells were deposited on top of a layer of printed collagen, subsequently 
crosslinked to immobilize the cells, and covered with an additional layer of collagen. 
Standard cell viability and proliferation assays showed that the printing technique did not 
affect cell viability. To explore the effect of growth factor release, a VEGF-releasing fibrin 
gel was added to the system. Whereas further studies should be conducted, initial experiments 
have shown that cellular proliferation and migration was supported over time. In a more 
advanced approach, Hsieh et al. explored bioprinting of cell-laden thermo-responsive 
biodegradable PU hydrogels.[71] Murine neural stem cells were harvested from adult mouse 
brain, encapsulated in different PU hydrogels, and subsequently bioprinted, forming a grid-
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like structure. Cell viability, proliferation, and gene expression analysis demonstrated its 
potential as a suitable niche for neuronal stem cell proliferation and differentiation. 
Furthermore, the potential of this strategy in central nervous repair was evaluated in zebrafish 
and embryo neural injury models, which demonstrated its potential to rescue central nervous 
system functioning. Whereas the above-mentioned approaches illustrate the potential of 
bioprinting technology for neuronal applications, these fabricated constructs are mainly 
constricted to relatively thin layers of cells within cell culture media or on top of a hydrogel.  
 
Given that the utility of actual bioprinting platforms for this particular application is at early 
stage, only a few studies have been reported in literature. One example is presented by our 
group and involves the development of a novel bioprinting-based method to recapitulate the 
layered structure of the brain and thereby fabricate 3D brain-like structures.[72] This study was 
based on previous work by Tang-Schomer et al., who developed compartmentalized 3D 
brain-like cortical tissue with silk fibroin-based biomaterials.[17] Our group developed an Arg-
Gly-Asp (RGD) peptide-modified gellan gum-based bioink (RGD-GG), which was assessed 
in terms of neural cytocompatibility, network formation, and printability. Discrete layers of 
cell-encapsulating (i.e. mouse primary neurons) RGD-GG were deposited using a simple 
hand-held printing device, resulting in layered constructs (Fig. 4(a-e)). Standard 
calcein/propodium iodide assays revealed acceptable cortical neuron and glial cell viability, 
both after encapsulation and printing RGD-GG. Immuno-staining seven days after 
encapsulation demonstrated neuronal network formation throughout the RGD-GG structures. 
To assess the potential of this strategy to create more complex multi-layered brain-like 
structures, six-layer structures were printed. Visual analysis revealed presence of distinct 
layers, within the solid structure. To assess the neural cytocompatibility of these larger 
structures, a three-layer construct was printed, consisting of two cell-laden RGD-GG layers, 
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separated by an acellular RGD-GG layer. Neuronal network formation was observed after 
five days of culture, with axons starting to penetrate into the acellular middle layer (Fig. 4(f-
g)). These multi-layer brain-like structures have shown to provide an environment in which 
the dynamic process of neural growth can be observed and quantified in 3D and thereby offer 
a promising tool for a variety of applications ranging from cell behaviour studies to 
understanding pathological conditions and drug testing.  
 
 
 
Figure 4. Layered brain-like structure: (a) SolidWorks schematic of the envisioned six-layered 
construct, (b-e) construct fabrication process, in which each colour represents a distinct layer, 
(f) confocal microscope images of the neurons coloured for their z-axis distribution after 5 
days of culture, (g) showing neurite penetration through the gel into the acellular RGD-GG 
layer. Scale bars represent 100 μm. Figure obtained and adapted from [72] with permission 
from Elsevier. 
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In another approach towards establishing more accurate neuronal tissue-like structures, our 
group investigated in situ differentiation of human neural stem cells in bioprinted 
constructs.[73] Frontal cortical human neural stem cells were encapsulated in an optimized 
polysaccharide bioink consisting of alginate, carboxymethyl-chitosan, and agarose, and 
followed by a micro-extrusion approach. Characterization of the cells revealed homogenous 
cell distribution and high viability throughout the printed construct. Immunophenotyping and 
reverse-transcription quantitative PCR (RT-qPCR) analysis demonstrated successful 
differentiation into functional neurons and supporting neuroglia, illustrating the potential of 
this platform to be used in translational studies. 
Following on from this study, Gu et al. described the first example of bioprinted human 
induced pluripotent stem cell constructs, which were successfully differentiated into 
homogenous neural tissues.[74] Human induced pluripotent stem cells were encapsulated in a 
bioink consisting of alginate (5% w/v), carboxymethyl-chitosan (5% w/v), and agarose (1.5% 
w/v) and subsequently bioprinted (Fig. 5(a)). Extrusion printing of the cell-laden bioink 
resulted in homogenous cell distribution throughout the constructs, with negligible cell death 
over a period of seven days, which was determined by standard calcein/propodium iodide 
assays (Fig. 5(b)).[74] Flow cytometry studies, performed after ten days in culture, revealed 
expression of pluripotency markers, which was further confirmed by induction of embryoid 
bodies. The bioprinted stem cells were then differentiated into cells with phenotypes that 
represent neuronal subtypes and microglia, as confirmed by immunophenotyping and RT-
qPCR. This study has successfully demonstrated the ability to produce human induced 
pluripotent stem cell-laden constructs and differentiate these into relevant cell types, which is 
an important step towards bioprinting-based neuronal tissue models. 
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Figure 5. Bioprinting of human induced pluripotent stem cells: (a) schematic representation of 
the approach, in which the bioink is prepared by adding the cells to an optimized alginate, 
carboxymethyl-chitosan, and agarose (Al-CMC-Ag) mixture and subsequently bioprinted. 
Cell viability studies by means of calcein/propidium iodide staining have shown (b) 
homogenous cell distributions and high cell viability over a period of seven days post-
printing. Scale bars represent 1 mm. Figure obtained and adapted from [74] with permission 
from John Wiley and Sons. 
 
 
Bioprinting, a complementary approach 
The true power of bioprinting technology lies in its superior potential to offer spatial and 
temporal control in a reproducible manner. However, it is important to realize that different 
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applications may require a different approach, which could be offered by other 3D cell culture 
platforms. Therefore, rather than being considered as superior, it is noteworthy to mention the 
complementary role of bioprinting technology, when being integrated with other existing 3D 
cell culture platforms.[75] Several papers have been reported regarding the integration of 
scaffold-free 3D cell culture platforms in combination with 3D printing technology. For 
example, Mironov et al. have demonstrated the potential of bioprinting to precisely deposit 
tissue spheroids formed from human dermal fibroblasts according to predefined patterns.[76] 
Very recently, Schneeberger et al. have reviewed the convergence of organoids and 
bioprinting technologies, highlighting the benefits bioprinting could have in terms of 
increasing the (clinical) application potential of organoids.[45] 
 
Besides its added value for scaffold fabrication, additive manufacturing could facilitate the 
development of custom-made microfluidics devices.[77] For example Johnson et al. used 
additive manufacturing technology to fabricate a nervous system-on-a-chip.[78] This 
biomimetic chip consisted of three chambers with separate fluid environments and 
microchannels, the latter providing axonal guidance and alignment (Fig. 6). The different 
compartments were loaded with appropriate cell types and the complete chip was studied over 
time in terms of cell organization and its potential to be applied in viral infection assays. 
Whereas spatial separation was indeed achieved, axonal networks were able to penetrate into 
the chambers, allowing axon-to-cell integration between compartments. In line with this, 
analysis of axon-to-cell spreading of viral particles from one compartment to another 
demonstrated biological connectivity between the compartments. In this approach, relevant 
cell types were successfully integrated on their chip, illustrating that additive manufacturing 
could be an effective fabrication approach for the development of tailor-made on-a-chip 
biomimicry devices.  
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Figure 6. 3D printed nervous-system-on-chip: (a) schematic of the printing approach, which 
consisted of three consecutive steps. First, microchannels providing axonal guidance were 
printed, subsequently, a sealant layer was printed, after which the individual chambers were 
fabricated. The chip was completed by (b) functionalizing the chambers with the relevant cell 
types. Obtained and modified from [78] with permission of The Royal Society of Chemistry. 
 
 
Future perspectives: challenges and opportunities 
Over the years, bioprinting technology has shown to offer great potential to establish 3D 
tissue-like constructs and thereby approximate in vivo like conditions. Even though 
bioprinting technology and its implications for the nervous system are still in its infancy, 
several important challenges that remain to be addressed are already identified: 1) systematic 
studies of cell-material and cell-ECM interactions in 3D to enable optimization of bioink 
formulations and scaffold design, 2) improved characterization methods to monitor the 
dynamic process of neural growth in 3D, such as tracking of cell migration and 
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differentiation, 3) coupling of high throughput screening methodologies with 3D printed 
neural systems for fundamental studies and pharmacological tests.  
Given its potential, research is increasingly turning to biofabrication technology to fabricate 
3D functional constructs. However, it is essential to bear in mind that biofabrication 
represents an integrated group of enabling technologies and disciplines, which together have 
as a common goal to develop biologically functional products.[24,79] As the biofabrication field 
matures, developments within all these converging technologies and disciplines become 
equally important and will need to be streamlined in order for the field to advance.  
 
The importance of converging disciplines 
Central to the biofabrication approach is the software, which is the starting point for construct 
design and drives the transition from this design phase to actual printing.[80] The software 
forms the basis for the quality and usability of the final construct, and should cover construct 
design and machine control in a user-friendly manner. It is essential to develop the software 
as well as the hardware, which can keep up with our enhanced understanding and appreciation 
of biofabrication-based tissue engineering and associated disciplines (e.g. the need for 
multiscale geometric complexity and multimaterial management). 
 
Another crucial pillar for the development of the biofabrication arena is the field of materials 
science. Key in the biofabrication discipline is the choice of the bioink. Regardless of the final 
application, this bioink should meet various general requirements, two crucial ones being its 
biocompatibility and printability. On the one hand, the bioink should resemble the native in 
vivo niche as closely as possible, which requires careful consideration of cellular behaviour, 
cellular functions, and -depending on the application- host integration. On the other hand, the 
bioink should exhibit appropriate viscous and mechanical properties, which enable accurate 
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deposition and shape-maintenance post-printing. Even though the scope of printable materials 
is expanding, to date, meeting both the requirements is hard to achieve, and usually involves a 
suboptimal, yet tolerable balance between both factors.[81] In order to advance the field, it is 
essential to develop more advanced biomaterials, which meet application-specific 
requirements. A relevant and exciting development is the emerging field of four-dimensional 
(4D) bioprinting, which is based on 3D bioprinting, but incorporates an extra fourth 
dimension in the form of ‘time’ to the system. 4D bioprinting goes hand-in-hand with 
developments in the area of smart stimuli-responsive materials.[82,83] These materials can be 
defined as materials that undergo a change in shape and/or function in response to an external 
stimulus such as temperature. Together, this facilitates the fabrication of constructs that can 
evolve over time after being printed, which makes it possible to add another level of 
complexity to the fabricated constructs, more closely resembling dynamic tissue 
conformations.  
Whereas the above-mentioned challenges are mostly centred on the pre-printing and printing 
phase, it is important to anticipate on post-printing issues. One important, yet limiting aspect 
is related to the lack of optimized methods to analyse and assess the more complex 3D 
structures. For decades, research was predominantly focussing on thin, optically transparent 
2D culture platforms, not only in terms of experimental design, but also in terms of 
subsequent data analysis. Whereas the increasing in vivo relevance that is offered by 3D cell 
culture platforms has its benefits, data interpretation becomes more challenging and requires 
developments in imaging technologies and establishing standard protocols. 
In order to bring biofabrication-based innovation from the bench to the clinic, it is not only 
necessary to look into the scientific and technical aspects, but also to look beyond. Key 
aspects to consider are the need for standardization in the field and the ethical considerations.  
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The need for standardization  
Among the abundant literature describing biofabrication and biofabrication approaches, a 
variety of ambiguous terms exist. [84,85] For example, terminology to describe the technology 
ranges from 3D printing, to bioprinting, additive manufacturing, additive biomanufacturing, 
and biofabrication, which are used interchangeably, often without being appropriately 
defined. This way of reporting could lead to potential confusion and makes it challenging to 
find relevant literature and compare results, which hinders knowledge transfer.  
If the field is to move forward, it is not only essential to establish standards in terms of 
terminology, but also in terms of experimental design, procedures, and performance. In this 
context, it is essential to develop a regulatory framework, which accounts for the potential of 
biofabrication technology to create tailor-made products that are integrated with living cells. 
As described in detail by Hourd et al. points of consideration do not only arise around testing 
and validation of these customizable products, but already at the stage of experimental 
design.[84] For example, successful implementation requires sufficient knowledge of the 
materials in terms of cytocompatibility, which indeed influences performance, but also on its 
reaction when subjected to the printing process and to its post-printing 
conditions/environment. One should take into account that it is not only about a relatively 
novel manner of manufacturing, but also about a complex product, with the potential to be 
placed in a dynamic environment. The true challenge lies in developing a regulatory 
environment in which products pass a set of standards and regulations, while retaining the 
customizable nature and ability to fabricate patient-specific products.  
 
Ethical considerations 
Whereas the biofabrication arena has substantial similarities with the fields of regenerative 
medicine and tissue engineering, the unique character of biofabrication technology and its 
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potential applications necessitates thorough biofabrication-specific ethical considerations.[86-
88] These involve questions related to the novelty of the technology itself, but also regarding 
its integration with biological products (e.g. stem cell technology). In addition, seen from a 
translational-application point of view, the great benefits that 3D biofabricated tissue products 
could offer in terms of personalised treatments raise their own ethical questions. From a 
preclinical ‘bench-side’ perspective, questions mainly arise around the use of animal and 
human materials. Several topics of debate are the choice and use of animals, use of cells 
sourced from embryonic and fetal tissues, and the privacy-related concerns associated with 
biobanking.[87,88] Other factors worth to consider include data integrity and appropriate study 
design, which could prevent premature transition from the bench to the bedside stage.[86] This 
bedside stage, which involves clinical trials, predominantly addresses questions related to the 
participants; selection of participants, and most importantly, the risks for the participant, 
which should be appropriate compared to the potential benefits on the larger scale. Lastly, 
there are society-related ethical considerations, which include the public’s perception of the 
biofabrication field. As with any emerging technology, this perception is highly influenced by 
the public media. To make scientific developments more accessible to the general audience, 
complex findings are usually presented with excessive enthusiasm, giving weight to particular 
aspects of the topic. Given the multidisciplinary character and unknown risks of 
biofabrication technology, biofabricated products, and their possible applications, it may be 
difficult to look beyond the hype. However, it is crucial to realize that the manner of reporting 
affects the public’s view on science. Overselling could easily lead to false expectations, 
disappointment, and eventually distrust in researchers and the technology. Sufficiently 
informing the public is essential for appropriate general understanding of science and could 
help when leading discussions on related topics (e.g. the role of biofabrication on human 
enhancement).  
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Conclusion 
The vast majority of our understanding of neurological disorders is based on simplified 2D 
cell culture experiments; an environment that profoundly differs from the dynamic native in 
vivo situation. To gain a better understanding of our nervous system, the associated disorders, 
and to develop effective therapeutics, more accurate and meaningful models are imperative. 
As discussed, bioprinting-based biofabrication approaches offer the potential to more 
accurately recapitulate tissue features. These models are envisioned to shed new light on the 
causes and the mechanisms underlying (neurodegenerative) diseases and improve and 
accelerate the translation of in vitro findings to clinically relevant applications. However, one 
should realize that biofabrication encompasses a variety of disciplines, requiring constructive 
collaboration between engineers, scientists, and clinicians. Successful implementation of a 
novel biotechnology such as biofabrication requires scientists to look beyond experimental 
design, keep the final application in mind, and consider the interplay between their research 
and associated (potential) ethical and regulatory issues. 
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